Evaluation of CpG Island Methylator Phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin

BACKGROUND: The CpG island methylator phenotype (CIMP) is a promising biomarker for irinotecan/5-fluorouracil/leucovorin chemotherapy in stage III colon cancer. In the present study, we evaluated whether CIMP is a prognostic biomarker for standard-of-care oxaliplatin-based adjuvant therapy. MATERIAL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Colorectal Cancer
Main Authors: Shiovitz, Stacey, Wu, Chen, Yu, Ming, Gourgioti, Georgia, Wirtz, Ralph, Raptou, Georgia, Gkakou, Chryssa, Kotoula, Vassiliki, Pentheroudakis, George, Papaxoinis, George, Karavasilis, Vasilios, Pectasides, Dimitrios, Kalogeras, Konstantine T., Fountzilas, George, Grady, William M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4864501/
https://ncbi.nlm.nih.gov/pubmed/26702772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2015.10.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados